ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BGC BTG

387.50
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
BTG LSE:BGC London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 387.50 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

BTG Share Discussion Threads

Showing 27501 to 27523 of 27550 messages
Chat Pages: 1102  1101  1100  1099  1098  1097  1096  1095  1094  1093  1092  1091  Older
DateSubjectAuthorDiscuss
29/5/2012
08:12
excellent progress each day
doctor 69
28/5/2012
22:30
why oh why would a massive company go to such efforts at this meeting . Surely ZTIGA ia heading to be a $2b blockbuster much quikcer than anyone thought.

Just think 3% net to BTG

doctor 69
28/5/2012
16:31
bargain looks like persistant interest from some people , great share
doctor 69
28/5/2012
12:36
Looks like someone expects news every morning before it settles back.
bargainbob
25/5/2012
13:02
RNS

TIDMBGC

BTG PLC

25 May 2012

BTG to present at the Jefferies Global Healthcare Conference
London, UK, 25 May 2012: BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York, US on Thursday, 7 June at 9.00am EDT (New York time), 2.00pm BST (London time).

The presentation will be uploaded to the BTG's website in the Investor/Results and Presentations area shortly after the presentation has concluded to ensure access for anyone unable to attend in person.

aquila2001
25/5/2012
08:29
going up strongly and some volume, interesting
doctor 69
23/5/2012
17:23
This was a solid performance in a really depressed market. This will start to climb once some sort of stability returns.
superbarnet
22/5/2012
21:36
LONDON (Dow Jones)-- BTG PLC (BGC.LN), the U.K specialty pharmaceutical company, is looking to spend the roughly GBP40 million it has at its disposal on bringing in specialty, late-stage drugs that will help to continue its growth.

"We are constantly looking at adding to our portfolio" the company's Chief Executive Officer Louise Makin told Dow Jones Newswires in an interview this week, adding that BTG would ideally like to stick with specialty pharmaceutical products.

bill hunt
22/5/2012
20:31
i have noticed in the past after btg results that there is often a pause for a few days and then the buying starts. Hope this is not the kiss of death.
doctor 69
22/5/2012
17:33
wywcu1

Three buy notes BB says buy up to 4.00

bargainbob
22/5/2012
15:44
This rise is really positive as people digest the results. The march north should continue.
superbarnet
22/5/2012
10:21
We have two BUY notices today - namely:
-
J.P.Morgan Cazenove buy with a revised target of £4.60 up from £4.15
-
HB Markets buy but no target given.

wywcu1
22/5/2012
06:31
And you have a director buying shares
doctor 69
21/5/2012
19:59
Impressive stuff!

Louise Makin will become a household name - mark my words!

cockneytrader
21/5/2012
18:41
A share price can be slashed even when good results are reported. It all depends on the analysts' expectations. I am delighted at the performance today as the price was little changed. The graph shows the long term direction and i will be adding over the next few weeks.
superbarnet
21/5/2012
18:19
Alord
The results did impress buyers , just they will come another day to buy . No one can fail to be impressed by these results

doctor 69
21/5/2012
17:22
Crazy market!
Why can't we celebrate and reward a SUCCESSFUL BRITISH COMPANY!!!

fhmktg
21/5/2012
10:45
I am doubting that Astra Zeneca will be interested to buy BTG:
1 They have already license agreement for CytoFab .
2 The rest of BTG pipeline is not for Astra's strategy.
3 I think that BTG will be looking around to buy , like LM mentioned at presentation today.
So IMO there will be no bid for BTG soon.
SP hopefully will be slowly growing after consolidation.

PS1 Jefferies has reiterated its buy recommendation and 410p target price for specialist healthcare company BTG (LSE: BGC.L - news) after the firm's full-year results this morning.
PS2 BTG (LSE: BGC.L - news) : Finncap raises to hold from sell

ANYBODY KNOWS WHAT RECOMMENDATIONS ISSUED OTHER BROKERS ? THANKS IN ADVANCE )))

I think results didnt impress buyers unfortunately despite better market today (((

a1ord53
21/5/2012
07:39
Solid results ahead of expectations with significant upside in coming years. Well done Louise & co!

Looking forward to re-commencing the rise back up towards where it belongs.

"On the mountains of truth you can never climb in vain: either you will reach a point higher up today, or you will be training your powers so that you will be able to climb higher tomorrow." Nietzsche


Good luck all.

moretimeforlife
21/5/2012
07:38
very strong results , the zytiga sales have really taken off and this looks like a £30m plus earner for this year. Really impressive and if you think only a a couple of monnths ago we expected sales of £160m this year and now we get £197m . stunnning
doctor 69
21/5/2012
07:25
A good read in the results everything positive. Apart from cautionary notes. Above 160 to 190 guidance.
bill hunt
20/5/2012
22:27
results time at btg is always little more than a damp squib. will tomorrow be any different? i do hope so!
cockneytrader
20/5/2012
19:32
Knock knock.... FT online




May 20, 2012 4:50 pm AstraZeneca looks to revive experimental drugs

AstraZeneca plans to seal several new deals this year to fill its flagging pipeline of experimental medicines, which may be funded jointly with private investors.

Martin Mackay, president of research and development at the Anglo-Swedish pharmaceutical group, told the Financial Times he would be "personally disappointed" if he had not concluded new agreements before the end of 2012.

He said that could include partnerships with other large drug companies, full acquisition of smaller quoted biotech companies and licensing deals for specific drugs developed by others.

waterloo01
Chat Pages: 1102  1101  1100  1099  1098  1097  1096  1095  1094  1093  1092  1091  Older

Your Recent History

Delayed Upgrade Clock